- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02797834
Isolation and Characterization of the Extracellular Vesicles Secreted by the Human Endometrium
Isolation and Characterization of the Extracellular Vesicles Secreted by the Human Endometrium to the Endometrial Fluid
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In the last decades, the emission of membrane enclosed compartments, more commonly regarded as extracellular vesicles, has been established as a new mechanism of communication either between cells of a complex organism, between unicellular organisms or between unicellular organism and host. These vesicles have been described in all body fluids and are currently classified into three types according to the mechanism by which they are formed: exosomes, with sizes ranging from 30 to 150 nm (formed intracellularly); microvesicles, between 100 and 1000 nm (formed from the cell membrane) and apoptotic bodies, with sizes greater than 1 µm (produced by cells undergoing programmed cell death).
Endometrial fluid is a viscous liquid present in the uterine cavity originating from the different cell types that form the uterus and serum exudates. It offers a precise view of the context in which the embryo implants and can be retrieved by a minimally invasive technique.
The main objective of this pilot study is to isolate and characterize the extracellular vesicles secreted by the endometrium to the endometrial fluid, being this the first time that this fact is being described. It is intended to standardize a method for the isolation of the different vesicles populations present within the endometrial fluid (i.e.: apoptotic bodies, microvesicles and exosomes), based on serial differential centrifugations and filtration. Morphological characterization of the isolated vesicles will be done at three levels: study of the external morphology by transmission electron microscopy, characterization of the different vesicles populations surface markers by Western Blot and analysis of the vesicles populations size distributions by Nanoparticle Tracking Analysis.
The second part of the study is directed to assess the content of the extracellular vesicles throughout the menstrual cycle. For this purpose, a canonical menstrual cycle of 28 to 30 days has been classified in 5 phases: phase I (days 0-8), phase II (days 9-14), phase III (days 15-18), phase IV (days 19-24) and phase V (25 to 30). The experimental design for vesicles contents description consists of two levels of comparison: (1) analysis of differential contents of the different populations of vesicles in the same phase of the menstrual cycle and for each of the phases and (2) analysis of differential contents of the same population of vesicles in each phase of the cycle and for each of the vesicular populations. This characterization of the vesicular contents will be made using mass spectrometry techniques to analyze the protein, lipid and other small metabolites composition. Their presence aims to be related both to the moment of the cycle and to a normal physiological function of the endometrium. On the other hand, analysis of DNA and RNA contents of these vesicular populations by massive sequencing will be performed. The objective here is to analyze the transmission of functionalities to target cells as well as the potential predictive usefulness of these molecules to determine the moment of the menstrual cycle.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Carlos Gomez, BSc MSc
- Phone Number: +34963905310
- Email: carlos.gomez@igenomix.com
Study Contact Backup
- Name: Diana Valbuena, MD PhD
- Phone Number: +34963905310
- Email: diana.valbuena@igenomix.com
Study Locations
-
-
-
Valencia, Spain, 46015
- Recruiting
- IVI Valencia
-
Contact:
- Carlos Simon, MD PhD
- Phone Number: +34963050900
- Email: carlos.simon@ivi.es
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Analysis in this study will be done using endometrial fluid samples retrieved from healthy, fertile, normal-cycling women which meet the inclusion/exclusion criteria.
These patients will be recruited in a single national centre: IVI Valencia. Their recruitment will be done during the routine clinical practice by the research group in the previously mentioned centre.
The research group will be in charge of checking patients' medical reports and getting in contact with those patients that meet the selection criteria and are willing to participate in the study.
Description
Inclusion Criteria:
- Healthy women in natural cycles.
- Age: 18 to 35 years (both included).
- Normal karyotype.
- Negative serological results for HIV, HBV, HBC, RPR.
- BMI: 18-30 Kg/m2 (both included).
- Regular menstrual cycle (3-4/28-30 days).
Exclusion Criteria:
- Patients who had carried a IUD device in the previous 3 months.
- Patients who had taken hormonal contraceptives in the previous 2 months.
- Adnexal or uterine pathologies.
- Polycystic ovary syndrome.
- Patients suffering from serious or uncontrolled bacterial, fungal or viral infectious diseases that could potentially interfere with the participation of the patient or with the results of the study (evaluated by the principal researcher of the research team).
- Any unstable disease or medical condition that could interfere with the study or put in risk the health of the patient (evaluated by the principal researcher of the research team).
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients Endometrial Fluid
Endometrial fluid samples from healthy and fertile women in their natural cycles, with ages ranging from 18 to 35 years, normal karyotype, negative for HIV, HBV, HCV and RPR, BMI ranging from 18 to 30 Kg/m2 (both included) and regular menstrual cycle (3-4/28-30 days). This unique assignment group will be divided into 5 subgroups attending to the moment of the menstrual cycle in which the patient could be classified: phase I (days 0-8), phase II (days 9-14), phase III (days 15-18), phase IV (days 19-24) and phase V (days 25-30). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Morphological characterization of the extracellular vesicles
Time Frame: 3 months
|
Assessment of the morphology of the extracellular vesicles using transmision electron microscopy by either ultrathin cuts and positive staining or deposition and positive staining techniques. The aim is to differentiate between vesicle populations thanks to their external aspects and size. |
3 months
|
Size distribution profiles characterization of the extracellular vesicles
Time Frame: 45 days
|
Analysis of the size distribution of the vesicles contained in the different extracellular vesicles populations by using two Nanoparticle Tracking Analysis techniques: ZetaSizer Nano and NanoSight300. The expected outcome is a set of graphs with size range data of the vesicles in the different populations and vesicle concentration data when using NanoSight300. |
45 days
|
Characterization of extracellular vesicles populations by specific markers
Time Frame: 45 days
|
Analysis of population-specific markers by Western Blot in order to further differentiate endometrial fluid vesicles populations. The aim is to differentiate populations based on the presence or absence of these markers. |
45 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Qualitative (names) and quantitative (expression levels) information about the different biomolecules that could be present in the samples: DNA, RNA, proteins, lipids and other small metabolites.
Time Frame: three years
|
three years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Felipe Vilella, BSc PhD, Igenomix
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1603-IGX-017-FV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Extracellular Vesicles
-
University of ReadingBiotechnology and Biological Sciences Research CouncilCompletedExtracellular Vesicles; Generation and FunctionUnited Kingdom
-
Aalborg University HospitalActive, not recruiting
-
Biological DynamicsDana-Farber Cancer Institute; Medical College of WisconsinRecruitingPancreatic Neoplasms | Pancreas Cancer | Extracellular Vesicles | ExosomesUnited States
-
Karolinska InstitutetDanderyd Hospital; Stockholm South General HospitalCompletedBrain Ischemia | Hemostasis | Prognosis | Cerebral Ischemia | Extracellular VesiclesSweden
-
Assistance Publique - Hôpitaux de ParisCompletedInjection Site VesiclesFrance
-
University of British ColumbiaCompletedExercise | Skeletal Muscle | Dietary Supplements | Extracellular Matrix | Amino Acids MetabolismCanada
-
CardioKine Inc.Biogen; Cardiokine Biopharma, LLCCompletedHyponatremia With Excess Extracellular Fluid Volume | Hyponatremia With Normal Extracellular Fluid VolumeUnited States
-
Azienda Ospedaliera Città della Salute e della...CompletedHyponatremia | Hyponatremia With Excess Extracellular Fluid Volume | Hyponatremia With Extracellular Fluid Depletion | Hyponatremia With Normal Extracellular Fluid VolumeItaly
-
Peking UniversityNot yet recruitingGuided Tissue Regeneration | Extracellular Matrix Scaffold of Small Intestinal Submucosa
-
University of CatanzaroCompletedCritical Limb Ischemia | Extracellular Matrix Alteration | Peripheral Revascularisation
Clinical Trials on Endometrial fluid collection
-
IgenomixStanford UniversityUnknownEndometrial Receptivity Diagnosis
-
IgenomixUniversity of Valencia; INCLIVATerminated
-
IgenomixCompletedInfertility of Uterine OriginUnited States, Argentina, Canada, Japan, Malaysia, Mexico, Spain, Turkey
-
IgenomixRecruitingInfertility of Uterine Origin | Implantation FailureBrazil, Spain, Peru, United Kingdom, United States, Panama
-
IgenomixUnknownFetal Origin of Adult DiseasesSpain
-
Stanford UniversityCompletedMicroRNA in Endometrial FluidUnited States
-
CHU de ReimsCompleted
-
Assistance Publique - Hôpitaux de ParisRecruitingHearing Loss, Cochlear | Cytomegalovirus CongenitalFrance
-
Istituto Ortopedico GaleazziCompletedPsoriasis | Psoriatic ArthritisItaly
-
University Health Network, TorontoRecruiting